Pentoxifylline Decreases Dialysis Risk in Patients with Advanced Chronic Kidney Disease
Journal
Clinical Pharmacology and Therapeutics
Journal Volume
98
Journal Issue
4
Pages
442-449
Date Issued
2015
Author(s)
Wu P.-C.
Wu C.-J.
Lin C.-J.
Pan C.-F.
Chen C.-Y.
Wu C.-H.
Chen L.
NSARF Group, Kidney Consortium
Abstract
Few studies evaluated the effects of pentoxifylline on hard endpoints in patients with predialysis stage 5 chronic kidney disease (CKD). Thus, we tried to explore the effects of pentoxifylline and its interaction with renin-angiotensin-aldosterone system (RAAS) blockade on the development of endstage renal disease (ESRD) andmortality. This nationwide cohort study retrospectively included patients who had a serum creatinine level of > 6mg/dL and received erythropoiesis-stimulating agents (ESAs) between 2000 and 2010.We analyzed 7,366 pentoxifylline users and 7,366 propensity score-matched nonusers. Using Cox proportional hazardmodels, pentoxifylline reduced the risks of ESRD and the composite renal outcome but not that of mortality. In terms of the risks of developing ESRD, pentoxifylline alone exerted a comparable beneficial effect to combined therapy with an RAAS inhibitor and greater renoprotection than RAAS inhibitormonotherapy. This study suggests pentoxifylline is efficacious in slowing progression to ESRD in patients with predialysis stage 5 CKD. ? 2015 American Society for Clinical Pharmacology and Therapeutics.
SDGs
Other Subjects
angiotensin receptor antagonist; creatinine; dipeptidyl carboxypeptidase inhibitor; pentoxifylline; angiotensin 1 receptor antagonist; biological marker; creatinine; dipeptidyl carboxypeptidase inhibitor; pentoxifylline; urinary tract agent; adult; Article; chronic kidney disease; cohort analysis; controlled study; creatinine blood level; dialysis; disease course; end stage renal disease; female; follow up; human; long term survival; major clinical study; male; monotherapy; mortality; prescription; priority journal; renal protection; renin angiotensin aldosterone system; retrospective study; risk reduction; aged; blood; chi square distribution; comparative study; drug combination; drug effects; Kidney Failure, Chronic; middle aged; multivariate analysis; pathophysiology; propensity score; proportional hazards model; Renal Insufficiency, Chronic; renal replacement therapy; risk factor; statistical model; time; treatment outcome; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Chi-Square Distribution; Creatinine; Disease Progression; Drug Therapy, Combination; Female; Humans; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pentoxifylline; Propensity Score; Proportional Hazards Models; Renal Dialysis; Renal Insufficiency, Chronic; Renin-Angiotensin System; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Urological Agents
Publisher
Nature Publishing Group
Type
journal article